Osteogenic commitment of Wharton's jelly mesenchymal stromal cells: mechanisms and implications for bioprocess development and clinical application

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Cabrera Pérez, Raquel
• dc.contributor.author Monguió Tortajada, Marta
• dc.contributor.author Gámez Valero, Ana
• dc.contributor.author Rojas Márquez, Raquel
• dc.contributor.author Borràs, Francesc Enric
• dc.contributor.author Roura, Santiago
• dc.contributor.author Vives, Joaquim
• dc.date.accessioned 2020-04-09T07:50:10Z
• dc.date.available 2020-04-09T07:50:10Z
• dc.date.issued 2019
• dc.description.abstract Background: Orthopaedic diseases are one of the major targets for regenerative medicine. In this context, Wharton’s jelly (WJ) is an alternative source to bone marrow (BM) for allogeneic transplantation since its isolation does not require an invasive procedure for cell collection and does not raise major ethical concerns. However, the osteogenic capacity of human WJ-derived multipotent mesenchymal stromal cells (MSC) remains unclear. Methods: Here, we compared the baseline osteogenic potential of MSC from WJ and BM cell sources by cytological staining, quantitative real-time PCR and proteomic analysis, and assessed chemical and biological strategies for priming undifferentiated WJ-MSC. Concretely, different inhibitors/activators of the TGFβ1-BMP2 signalling pathway as well as the secretome of differentiating BM-MSC were tested. Results: Cytochemical staining as well as gene expression and proteomic analysis revealed that osteogenic commitment was poor in WJ-MSC. However, stimulation of the BMP2 pathway with BMP2 plus tanshinone IIA and the addition of extracellular vesicles or protein-enriched preparations from differentiating BM-MSC enhanced WJ-MSC osteogenesis. Furthermore, greater outcome was obtained with the use of conditioned media from differentiating BM-MSC. Conclusions: Altogether, our results point to the use of master banks of WJ-MSC as a valuable alternative to BM-MSC for orthopaedic conditions.
• dc.format.mimetype application/pdf
• dc.identifier.citation Cabrera-Pérez R, Monguió-Tortajada M, Gámez-Valero A, Rojas-Márquez R, Borràs FE, Roura S, Vives J. Osteogenic commitment of Wharton's jelly mesenchymal stromal cells: mechanisms and implications for bioprocess development and clinical application. Stem Cell Res Ther. 2019; 10(1):356. DOI: 10.1186/s13287-019-1450-3
• dc.identifier.doi http://dx.doi.org/10.1186/s13287-019-1450-3
• dc.identifier.issn 1757-6512
• dc.identifier.uri http://hdl.handle.net/10230/44192
• dc.language.iso eng
• dc.publisher BioMed Central
• dc.relation.ispartof Stem Cell Res Ther. 2019; 10(1):356
• dc.rights © The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by/4.0/
• dc.subject.keyword Mesenchymal stromal cells
• dc.subject.keyword Bone marrow
• dc.subject.keyword Wharton’s jelly
• dc.subject.keyword Osteogenic differentiation
• dc.subject.keyword Bone regeneration
• dc.title Osteogenic commitment of Wharton's jelly mesenchymal stromal cells: mechanisms and implications for bioprocess development and clinical application
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion